Effects of prazosin and propranolol on blood lipids and lipoproteins in hypertensive patients
| Autor: | Manuel Velasco, Edgardo Feldstein, Eva Hurt, Otto Hernandez-Pieretti, German Camejo, Adalberto Urbina-Quintana, Honorio Silva |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
Adult
Male medicine.medical_specialty Very low-density lipoprotein Lipoproteins Cholesterol VLDL Blood lipids Blood Pressure Propranolol Lipoproteins VLDL chemistry.chemical_compound Random Allocation Heart Rate Internal medicine Prazosin Medicine Humans Apolipoproteins A Triglycerides Aged Clinical Trials as Topic Apolipoprotein A-I business.industry Cholesterol General Medicine Cholesterol LDL Middle Aged Lipid Metabolism Crossover study Lipids Mean blood pressure Endocrinology Blood pressure chemistry Hypertension lipids (amino acids peptides and proteins) business medicine.drug |
| Zdroj: | The American journal of medicine. 80(2A) |
| ISSN: | 0002-9343 |
| Popis: | Prazosin and propranolol were compared in an open, crossover study to determine their effects on plasma lipids and lipoproteins. After a four-week placebo period, 10 hypertensive patients were randomly assigned to prazosin treatment (Group I) and another 10 to propranolol treatment (Group II) for eight weeks. After a second four-week placebo period, treatment in each group was switched to the alternative drug for eight weeks. The mean blood pressure was reduced to normal levels (diastolic blood pressure less than or equal to 90 mm Hg) by both drugs--prazosin (1 to 8 mg per day) and propranolol (40 to 240 mg per day). The results of the study indicate that prazosin decreases serum cholesterol levels. In contrast, propranolol not only increases serum triglyceride levels and very-low-density lipoprotein cholesterol, but decreases total high-density lipoprotein cholesterol, high-density lipoprotein2 cholesterol, high-density lipoprotein2, and apoprotein A-I. The data suggest that propranolol may induce significant, potentially atherogenic changes in lipid metabolism, whereas prazosin may represent an advantageous alternative as an antihypertensive agent, especially in subjects with an already atherogenic lipoprotein profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|